Update - EpiPen® 300mcg adrenaline (epinephrine) autoinjectors supply - 13 Feb 2018

ASCIA has now updated information on the EpiPen® 300mcg shortage

Mylan has advised that normal stock of EpiPen® 300mcg adrenaline autoinjectors is expected to be available in pharmacies by late February 2018. A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may need.

Currently there is no shortage of EpiPen® Jr 150mcg adrenaline autoinjectors. If a pharmacy is out of stock of EpiPen® Jr, the pharmacist should contact their wholesaler/s to obtain stock. If there are any problems they should phone Mylan on 1800 274 276.

We suggest that patients requiring an EpiPen® 300mcg autoinjector take their expired, soon to be expired, or used (if available) EpiPen® device/s to their local pharmacy. Pharmacists should then contact Mylan (phone 1800 274 276 or email This email address is being protected from spambots. You need JavaScript enabled to view it.) to obtain instructions on how to access emergency supply.  

Individuals will be able to access one in-date adrenaline autoinjector until the shortage resolves by late February 2018.  It is important to note that a device expiring in February 2018 does not actually expire until the end of that month, not the start of that month. Patients should retain their recently expired autoinjector/s (see information below).

In the case of anaphylaxis, patients and/or carers should follow instructions on their ASCIA Action Plan www.allergy.org.au/anaphylaxis (Give EpiPen® and call an ambulance by phoning 000 AU or 111 NZ). 

Patients and/or carers who require support should contact the national patient support organisations, Allergy & Anaphylaxis Australia (phone 1300 728 000 or contact us) or Allergy New Zealand  www.allergy.org.nz

Use of expired adrenaline autoinjectors

Whilst the use of an expired adrenaline autoinjector is not ideal, research suggests that recently expired devices retain potency. Therefore, if no other adrenaline autoinjector is available, use of a recently expired device to treat anaphylaxis is advised, as stated on the ASCIA website: www.allergy.org.au/health-professionals/anaphylaxis-resources/adrenaline-autoinjector-storage-expiry-and-disposal

ASCIA Website 

www.allergy.org.au/about-ascia/info-updates/update-epipen-300mcg-adrenaline-epinephrine-autoinjectors-supplynjectors-supply 

Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond


Viatris
Sanofi
Nestle
Allergy Concepts

Platinum


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer

Gold


  • dbv technologies
  • Mondelez
  • Nurticia
Silver

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William


© 2023 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 



ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.


ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.